Redeye views the agreement with Eli Lilly, close second in the obesity space after Novo Nordisk, as strong validation of its FluidCrystal pl...
Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi sales were flat Q/Q on a constant FX ba...
Redeye provides its first take on Camurus’ Q1 report 2025, published this morning.
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annu...
